2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15407AS
    Sacubitril-13C4 hemicalcium salt 98%
    Sacubitril-13C4 (hemicalcium salt) is a 13C-labeled and deuterium labeled Sacubitril hemicalcium salt. Sacubitril (AHU-377) hemicalcium salt is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.
    Sacubitril-13C4 hemicalcium salt
  • HY-15407BR
    Sacubitril sodium (Standard) 149690-05-1
    Sacubitril (sodium) (Standard) is the analytical standard of Sacubitril (sodium). This product is intended for research and analytical applications. Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19.
    Sacubitril sodium (Standard)
  • HY-15731S1
    Estetrol-d4 (Major) 2734920-42-2
    Estetrol-d4 (Major) is the deuterium labeled Estetrol (HY-15731). Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research.
    Estetrol-d4 (Major)
  • HY-157639A
    18:2 Lyso PA sodium 98%
    18:2 Lyso PA sodium is an unsaturated lysophosphatidic acid (LysoPA), a lipid mediator mainly present in plasma and thought to be involved in the pathogenesis of acute coronary syndrome (ACS). 18:2 Lyso PA sodium significantly correlates with serum autotaxin (ATX) in peripheral arteries.
    18:2 Lyso PA sodium
  • HY-158186S
    Bisoprolol-d6 hemifumarate 98%
    Bisoprolol-d6 fumarate is deuterium labeled Bisoprolol (hemifumarate). Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
    Bisoprolol-d6 hemifumarate
  • HY-15834AR
    Eprosartan mesylate (Standard) 144143-96-4
    Eprosartan (mesylate) (Standard) is the analytical standard of Eprosartan (mesylate). This product is intended for research and analytical applications. Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan mesylate binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively.
    Eprosartan mesylate (Standard)
  • HY-159002S
    Methyl-warfarin-d3 98%
    Methyl-warfarin-d3 is a deuterated labeling methylated Warfarin (HY-B0687).
    Methyl-warfarin-d3
  • HY-167079A
    OPC-18750 hydrochloride 145364-90-5 98%
    OPC-18750 hydrochloride has positive inotropic and coronary vasodilatory effects.
    OPC-18750 hydrochloride
  • HY-172281A
    DSPE-PEG2000-CCK8 98%
    DSPE-PEG2000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG2000-CCK8 can be used for drug delivery.
    DSPE-PEG2000-CCK8
  • HY-172281B
    DSPE-PEG5000-CCK8 98%
    DSPE-PEG5000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG5000-CCK8 can be used for drug delivery.
    DSPE-PEG5000-CCK8
  • HY-172687A
    DSPE-PEG3400-CSTSMLKAC
    DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery.
    DSPE-PEG3400-CSTSMLKAC
  • HY-172836S
    GLP-1 receptor agonist 17-d3 3074098-20-4 98%
    GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
    GLP-1 receptor agonist 17-d3
  • HY-17356S1
    Fenofibrate-d4 1092484-57-5 98%
    Fenofibrate-d4 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-d4
  • HY-17369BS
    Tirofiban-d9 1332075-40-7 98%
    Tirofiban-d9 is deuterium labeled Tirofiban.
    Tirofiban-d9
  • HY-17402S3
    Nisoldipine-d3 98%
    Nisoldipine-d3 is deuterated labeled Nisoldipine (HY-17402). Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.
    Nisoldipine-d3
  • HY-17412AS
    Minocycline-d6 1036070-10-6 98%
    Minocycline-d6 is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6
  • HY-17436S1
    Clevidipine-d7 98%
    Clevidipine-d7 is the deuterium labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.
    Clevidipine-d7
  • HY-17436S3
    (R)-Clevidipine-13C,d3 98%
    (R)-Clevidipine-13C,d3 is the deuterium and 13C labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.
    (R)-Clevidipine-13C,d3
  • HY-17436S4
    Clevidipine-15N,d10 98%
    Clevidipine-15N,d10 is 15N and deuterated labeled Clevidipine (HY-17436). Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H)=-40 mV ).
    Clevidipine-15N,d10
  • HY-17464S1
    Cilostazol-d4 1215541-47-1 98%
    Cilostazol-d4 is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.
    Cilostazol-d4
Cat. No. Product Name / Synonyms Application Reactivity